Calamos Advisors LLC Acquires 1,048 Shares of Vertex Pharmaceuticals Incorporated $VRTX

by · The Cerbat Gem

Calamos Advisors LLC lifted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 1.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 76,436 shares of the pharmaceutical company’s stock after purchasing an additional 1,048 shares during the period. Calamos Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $39,962,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Community Financial Services Group LLC bought a new position in shares of Vertex Pharmaceuticals in the second quarter valued at $26,000. Meeder Asset Management Inc. acquired a new stake in shares of Vertex Pharmaceuticals during the second quarter worth $26,000. MADDEN SECURITIES Corp acquired a new stake in shares of Vertex Pharmaceuticals during the third quarter worth $26,000. Elevation Wealth Partners LLC lifted its holdings in shares of Vertex Pharmaceuticals by 103.7% during the second quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 28 shares during the last quarter. Finally, Pingora Partners LLC acquired a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at $32,000. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ VRTX traded up $4.59 during mid-day trading on Friday, reaching $547.09. The company had a trading volume of 1,271,220 shares, compared to its average volume of 1,509,185. Vertex Pharmaceuticals Incorporated has a twelve month low of $406.67 and a twelve month high of $568.67. The stock has a market capitalization of $138.85 billion, a PE ratio of 35.21, a price-to-earnings-growth ratio of 2.65 and a beta of 0.28. The stock’s 50 day moving average is $522.80 and its 200-day moving average is $481.95.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). The firm had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.42 billion. Vertex Pharmaceuticals had a net margin of 30.70% and a return on equity of 22.40%. Vertex Pharmaceuticals’s revenue for the quarter was up 11.8% on a year-over-year basis. During the same period in the previous year, the business posted $4.80 EPS. On average, sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 16.47 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Sanford C. Bernstein upgraded Vertex Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, July 29th. Truist Financial raised their price objective on shares of Vertex Pharmaceuticals from $560.00 to $565.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Rothschild & Co Redburn raised their target price on Vertex Pharmaceuticals from $570.00 to $580.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings raised Vertex Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, October 16th. Finally, Leerink Partners started coverage on Vertex Pharmaceuticals in a research note on Monday, September 21st. They issued an “outperform” rating and a $594.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $596.44.

Check Out Our Latest Stock Analysis on VRTX

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

  • Positive Sentiment: Several analysts reiterated bullish views or raised price targets, including Barclays, Maxim Group, TD Cowen, JPMorgan, Goldman Sachs and Stifel. These updates support the case for further share-price appreciation, though the articles do not provide the revised target figures. Read More. · Read More. · Read More. · Read More.
  • Positive Sentiment: A long-term bullish outlook points to Vertex’s strong cystic fibrosis franchise and its gradual diversification into additional businesses as potential drivers of continued growth. A separate report says core business growth remains steady and diversification is beginning to contribute. Read More. · Read More.
  • Neutral Sentiment: Vertex said management will participate in three upcoming investor conferences. The appearances may provide updates, but the announcement itself does not disclose new business or financial information. Read More.
  • Negative Sentiment: A bearish analysis argues that costs are growing faster than sales and that Vertex may need another major growth driver to justify its valuation. This highlights execution and pipeline risks as investors assess whether diversification can sustain growth. Read More.
  • Negative Sentiment: Not all analysts are more optimistic: Morgan Stanley lowered its expectations for the stock, providing a counterpoint to the recent target increases. Read More.

Vertex Pharmaceuticals Profile

(Free Report)

Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF).

Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.

Vertex serves patients in the United States and international markets, including Europe.

Recommended Stories

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).